AbbVie Exceeds First-Quarter 2026 Earnings and Raises Full-Year Forecast
AbbVie exceeded first-quarter 2026 earnings and raised its full-year adjusted earnings forecast, driven by strong performance in its immunology drugs Skyrizi and Rinvoq. The company reported first-quarter net revenues of $15 billion, a 12.4% increase, and set a new full-year adjusted diluted earnings target of $14.08 to $14.28 per share.
Tickers: $ABBV
Topics: Biosimilars Drug Sales Earnings Humira Immunology Portfolio Performance Revenue Growth